Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial

Trial Profile

Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms EU OPTILIV trial; OPTILIV
  • Most Recent Events

    • 17 Aug 2017 Results (n=52) of pharmacogenetic assessment in OPTILIV published in the British Journal of Cancer
    • 06 Jun 2017 Results of pharmacogenomic predictors of response and survival presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 06 Jun 2017 Results assessing pharmacogenomic determinants presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top